| Image Class: | skin-invert-image |
| Width: | 250px |
| Class: | Serotonin releasing agent |
| Atc Prefix: | None |
| Legal Status: | Uncontrolled |
| Index2 Label: | hydrochloride |
| Cas Number: | 101625-35-8 |
| Cas Number2: | 3446-21-8 |
| Unii: | 28IR5LC41Q |
| Unii2: | BOX4U52EET |
| Pubchem: | 36483 |
| Chemspiderid: | 33531 |
| Synonyms: | 6,7-MDAT; 6,7-Methylenedioxy-2-aminotetralin |
| Iupac Name: | 5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-6-amine |
| C: | 11 |
| H: | 13 |
| N: | 1 |
| O: | 2 |
| Smiles: | C3Cc1cc2OCOc2cc1CC3N |
MDAT, also known as 6,7-methylenedioxy-2-aminotetralin, is a drug of the 2-aminotetralin family developed in the 1990s by a team at Purdue University led by David E. Nichols.[1] It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity.[1] Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.
